ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 184126" data-attributes="member: 13851"><p><strong>Context:</strong> <em><span style="color: rgb(184, 49, 47)">Hypogonadism is a well-established consequence of opioid use. It has been reported in both men and women, although more widely studied in men. </span></em></p><p></p><p><strong>Evidence Acquisition:</strong> PubMed was searched for articles in English until December 2019 for opioids and hypogonadism. Bibliography of retrieved articles was searched for relevant articles.</p><p></p><p><strong>Evidence Synthesis:</strong> The prevalence of opioid-induced hypogonadism (OIH) varies between studies but was reported to be 69% in a recent systematic review. There is large heterogeneity in the studies, with different factors shown to have a stronger association with hypogonadism such as specific types of opioids, higher doses, and longer durations of use. The consequences of OIH include sexual dysfunction, depression, decreased quality of life, and low bone density. There is a paucity of randomized controlled trials assessing the efficacy of testosterone replacement therapy (TRT) for OIH in men, and even fewer studies on treating OIH in women. TRT studies in men reported varying outcomes with some studies favoring and others showing no clear benefit of TRT on different measures.</p><p></p><p><strong>Conclusions: </strong><em><span style="color: rgb(184, 49, 47)">Despite the high prevalence of OIH, it remains underrecognized and undertreated with multiple endocrine and metabolic consequences</span></em>. A reasonable approach in patients using opioids includes informing them of this complication and its potential consequences, screening for signs and symptoms of hypogonadism then sex hormone levels if prolonged opioid use > 3 months, and treating patients diagnosed with hypogonadism, if and when clinically indicated, with sex hormones if chronic opioids are planned to be continued for ≥ 6 months. (J Clin Endocrinol Metab 105: 1–9, 2020)</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Conclusion </strong></p><p></p><p><em><strong><span style="color: rgb(184, 49, 47)">Opioid-induced hypogonadism is a well-established problem during the opioid epidemic, with a high prevalence of 69% reported based on a recent systematic review and meta-analysis (17). The prevalence in the literature varies widely depending on multiple factors, such as the definition of hypogonadism, type and duration of action of opioid, and dose, indication, and duration of opioid use. Opioid-induced hypogonadism has multiple endocrine and metabolic consequences including reduced quality of life, sexual dysfunction, and low BMD.</span></strong></em> <em><span style="color: rgb(44, 130, 201)"><strong>However, there is a paucity of RCTs assessing the efficacy of TRT in male opioid-induced hypogonadism and there are even fewer studies on treating opioid-induced hypogonadism in women. The studies evaluating TRT in men are mostly observational, with conflicting results. We need more RCTs to better inform our treatment decisions and assess the benefits of TRT in this population. Despite our lack of understanding of the effects of TRT on opioid-induced hypogonadism in men, it might be reasonable to consider treatment to improve bone health and possibly sexual dysfunction symptoms because of the discontinuation or at least dose reduction of opioids is not always feasible.</strong> </span><span style="color: rgb(184, 49, 47)"><strong>Given the lack of recognition of this condition, it is important for endocrinologists to recognize, screen for, diagnose, and treat this condition, in the absence of contraindications, to possibly improve patient outcomes. A reasonable approach is outlined in Figure 2 and would include informing all patients on opioids or planned to start prolonged opioid treatment of this complication to the gonadal axis and its potential consequence, screening all patients on chronic opioids for more than 3 months for signs and symptoms of hypogonadism and sex hormone levels if present, and treating patients diagnosed with hypogonadism, if clinically indicated, with sex hormones if chronic opioids are planned to be continued for at least 6 months. </strong></span></em></p><p></p><p></p><p></p><p></p><p>.</p></blockquote><p></p>
[QUOTE="madman, post: 184126, member: 13851"] [B]Context:[/B] [I][COLOR=rgb(184, 49, 47)]Hypogonadism is a well-established consequence of opioid use. It has been reported in both men and women, although more widely studied in men. [/COLOR][/I] [B]Evidence Acquisition:[/B] PubMed was searched for articles in English until December 2019 for opioids and hypogonadism. Bibliography of retrieved articles was searched for relevant articles. [B]Evidence Synthesis:[/B] The prevalence of opioid-induced hypogonadism (OIH) varies between studies but was reported to be 69% in a recent systematic review. There is large heterogeneity in the studies, with different factors shown to have a stronger association with hypogonadism such as specific types of opioids, higher doses, and longer durations of use. The consequences of OIH include sexual dysfunction, depression, decreased quality of life, and low bone density. There is a paucity of randomized controlled trials assessing the efficacy of testosterone replacement therapy (TRT) for OIH in men, and even fewer studies on treating OIH in women. TRT studies in men reported varying outcomes with some studies favoring and others showing no clear benefit of TRT on different measures. [B]Conclusions: [/B][I][COLOR=rgb(184, 49, 47)]Despite the high prevalence of OIH, it remains underrecognized and undertreated with multiple endocrine and metabolic consequences[/COLOR][/I]. A reasonable approach in patients using opioids includes informing them of this complication and its potential consequences, screening for signs and symptoms of hypogonadism then sex hormone levels if prolonged opioid use > 3 months, and treating patients diagnosed with hypogonadism, if and when clinically indicated, with sex hormones if chronic opioids are planned to be continued for ≥ 6 months. (J Clin Endocrinol Metab 105: 1–9, 2020) [B]Conclusion [/B] [I][B][COLOR=rgb(184, 49, 47)]Opioid-induced hypogonadism is a well-established problem during the opioid epidemic, with a high prevalence of 69% reported based on a recent systematic review and meta-analysis (17). The prevalence in the literature varies widely depending on multiple factors, such as the definition of hypogonadism, type and duration of action of opioid, and dose, indication, and duration of opioid use. Opioid-induced hypogonadism has multiple endocrine and metabolic consequences including reduced quality of life, sexual dysfunction, and low BMD.[/COLOR][/B][/I] [I][COLOR=rgb(44, 130, 201)][B]However, there is a paucity of RCTs assessing the efficacy of TRT in male opioid-induced hypogonadism and there are even fewer studies on treating opioid-induced hypogonadism in women. The studies evaluating TRT in men are mostly observational, with conflicting results. We need more RCTs to better inform our treatment decisions and assess the benefits of TRT in this population. Despite our lack of understanding of the effects of TRT on opioid-induced hypogonadism in men, it might be reasonable to consider treatment to improve bone health and possibly sexual dysfunction symptoms because of the discontinuation or at least dose reduction of opioids is not always feasible.[/B] [/COLOR][COLOR=rgb(184, 49, 47)][B]Given the lack of recognition of this condition, it is important for endocrinologists to recognize, screen for, diagnose, and treat this condition, in the absence of contraindications, to possibly improve patient outcomes. A reasonable approach is outlined in Figure 2 and would include informing all patients on opioids or planned to start prolonged opioid treatment of this complication to the gonadal axis and its potential consequence, screening all patients on chronic opioids for more than 3 months for signs and symptoms of hypogonadism and sex hormone levels if present, and treating patients diagnosed with hypogonadism, if clinically indicated, with sex hormones if chronic opioids are planned to be continued for at least 6 months. [/B][/COLOR][/I] . [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top